Use of an acute challenge with d‐amphetamine to model cognitive improvement in chronic schizophrenia
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
There is general agreement that pharmacologic improvement of cognition in chronic schizophrenia is a worthwhile therapeutic goal. Accordingly, there has been careful consideration about how neuropsychological methods can be used to detect improvement in cognition in people with schizophrenia. However, little data are available on the nature and magnitude of cognitive improvement that can occur with adjunctive therapeutic interventions. This double‐blind, placebo‐controlled crossover study examined the nature and magnitude of cognitive enhancement associated with a single‐dose administration of d‐amphetamine in 32 adult men with schizophrenia using a set of tasks developed specifically for detecting treatment‐related change in cognitive function. Relative to placebo, acute d‐amphetamine administration was associated with clinically meaningful improvement on measures of executive function and visual attention and vigilance, and with modest improvements on a measure of speed of processing. These results suggest that a brief computerized cognitive test battery designed for repeat administration, in combination with a statistical approach that emphasizes individual‐level change, provides a sensitive approach to detecting the effect of cognitive‐enhancing medications in people with chronic schizophrenia. Copyright © 2010 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., Essock, S., Fenton, W. S., Frese, F. J., Gold, J. M., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010042 · Cited by 2,342
The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization
Kern, R. S., Nuechterlein, K. H., Green, M. F., Baade, L. E., Fenton, W. S., Gold, J. M., Keefe, R. S. E., Mesholam-Gately, R., Mintz, J., Seidman, L. J., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010043 · Cited by 744
Maruff, P., Thomas, E., Cysique, L., Brew, B., Collie, A., Snyder, P., & Pietrzak, R. H. (2009) · Archives of Clinical Neuropsychology · doi:10.1093/arclin/acp010 · Cited by 635
Self-citationBuchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi020 · Cited by 438 · cited 1×
“These clinical rating scales are used extensively in clinical trials of schizophrenia where their reliability and validity has been well established (e.g., Buchanan et al., 2005).”
MethodBarch, D. M., & Carter, C. S. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2004.12.019 · Cited by 222
Modulation of use‐dependent plasticity by d‐amphetamine
Bütefisch, C. M., Davis, B. C., Sawaki, L., Waldvogel, D., Classen, J., Kopylev, L., & Cohen, L. G. (2002) · Annals of Neurology · doi:10.1002/ana.10056 · Cited by 182 · cited 2×
“Doses of damphetamine as low as 10mg have been shown to enhance dopaminergic transmission (Bütefisch et al., 2002; Ziemann et al., 2002) aswell as cognitive function (Fillmore et al.”
BackgroundMattay, V. S., Berman, K. F., Ostrem, J. L., Esposito, G., Van Horn, J. D., Bigelow, L. B., & Weinberger, D. R. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-15-04816.1996 · Cited by 151 · cited 2×
“Damphetaminemay enhance cognitive efficiency on tasks that assess these functions by increasing signal-to-noise ratio, as evidenced by increased regional cerebral blood flow in the right hippocampus during performance on executive function tasks such as the Wisconsin Card Sorting Test (Mattay et al., 1996) and by modu…”
MethodThe acute effects of d-amphetamine and methamphetamine on attention and psychomotor performance
Silber, B. Y., Croft, R. J., Papafotiou, K., & Stough, C. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0410-7 · Cited by 140 · cited 3×
“Based on prior research (e.g., Barch and Carter, 2005; Silber et al., 2006), we hypothesized that administration of d-amphetamine would be associated with improvement in attention and executive function.”
BackgroundMethod
Cited by
The treatment of cognitive impairment in schizophrenia
Goff, D. C., Hill, M., & Barch, D. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.11.009 · Cited by 194
Morrow, S. A., Smerbeck, A., Patrick, K., Cookfair, D., Weinstock-Guttman, B., & Benedict, R. H. B. (2013) · Journal of Neurology · doi:10.1007/s00415-012-6663-7 · Cited by 40
Koychev, I., Barkus, E., Ettinger, U., Killcross, S., Roiser, J. P., Wilkinson, L., & Deakin, B. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111414450 · Cited by 24
“The empirical evidence suggests acute amphetamine challenge improves rather than disrupts cognition in patients with schizophrenia (Pietrzak et al., 2010).”
BackgroundPharmacological Treatment of Cognitive Dysfunction in Neuropsychiatric Disorders
Venero, C. (2015) · Cognitive Enhancement · doi:10.1016/b978-0-12-417042-1.00010-3 · Cited by 4
Metadata
- Authors
- Pietrzak, R. H., Snyder, P. J., & Maruff, P.
- Venue
- Human Psychopharmacology: Clinical and Experimental
- Publisher
- Wiley
- Published
- 2010-05-28
- Volume
- 25
- Issue
- 4
- Pages
- 353-358
- ISSN
- 0885-6222 (ISSN-L)
- 1099-1077
- OpenAlex
- W2126582286
- Cited by
- 39
- References
- 8
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of an acute challenge with d‐amphetamine to model cognitive improvement in chronic schizophrenia. https://app.cochat.ai/papers/10.1002/hup.1118
- The paper
- Pietrzak, R. H., Snyder, P. J., & Maruff, P. (2010). Use of an acute challenge with d‐amphetamine to model cognitive improvement in chronic schizophrenia. Human Psychopharmacology: Clinical and Experimental. https://doi.org/10.1002/hup.1118
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.